Microba Life Sciences (ASX:MAP) Volatility: 51.73% (As of Jun. 25, 2026)


What is Microba Life Sciences Volatility?

Microba Life Sciences ASX:MAP Volatility is 51.73% as of Jun. 25, 2026. The stock has 6 warning signs investors should review.

Volatility is a statistical measure of the dispersion of returns for a given security or market index, it shows how the price swings around its mean. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year. In most cases, the higher the volatility, the riskier the security.

As of today (2026-06-25), Microba Life Sciences's Volatility is 51.73%.

Microba Life Sciences  (ASX:MAP) Volatility Explanation

Volatility is a statistical measure of the dispersion of returns for a given security or market index. It’s often measured as standard deviation or variance of historical returns over a certain period. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year.

Volatility reflects the uncertainty or risk of a security’s value. Generally speaking, a higher volatility suggests a higher risk, because it implies a wider fluctuation around average price. This means the price of the security can change dramatically in either direction within a short period. Conversely, a lower volatility means that the security's price is more steady, which suggests a lower risk.

Another measurement of relative volatility is Beta. Beta is a measure of systematic risk of a security or a portfolio in comparison to the market as a whole. Beta is usually compared to 1. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Microba Life Sciences Volatility Related Terms

ASX:MAP vs TMO, DHR, IDXX: Volatility Comparison

For the Diagnostics & Research subindustry, Microba Life Sciences's Volatility, along with its competitors' market caps and Volatility data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Microba Life Sciences Volatility vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Microba Life Sciences's Volatility distribution charts can be found below:

* The bar in red indicates where Microba Life Sciences's Volatility falls into.


Microba Life Sciences  (ASX:MAP) Volatility Calculation

The annualized volatility is calculated as following:

σA=σM * √12
=√ 1/(n-1) ∑(Ri - R')^2 * √12

Where: σM is the monthly volatility, n is the number of months in the period, Ri is the security's historical monthly returns and R' is the arithmetic mean of monthly returns.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Volatility →
What does a Volatility of 51.73% mean?
Microba Life Sciences (ASX:MAP) has a Volatility of 51.73% as of Jun. 25, 2026. Volatility is measured as the annualized standard deviation between monthly returns from the security over the past year. View historical data on Microba Life Sciences and its competitors.
Is Microba Life Sciences' Volatility too high?
Microba Life Sciences' current Volatility is 51.73%.
How does Microba Life Sciences' Volatility compare to TMO and DHR?
Microba Life Sciences' Volatility of 51.73% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Volatility for a Medical Diagnostics & Research company?
A good Volatility depends on the Medical Diagnostics & Research industry context. However, Volatility should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Volatility mean?
A high Volatility can signal that a stock is expensive relative to its fundamentals. Volatility is measured as the annualized standard deviation between monthly returns from the security over the past year. View historical data on Microba Life Sciences and its competitors. Microba Life Sciences's current Volatility is 51.73%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Microba Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Microba Life Sciences (ASX:MAP) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.25, compared to a current price of A$0.04 — trading 84.4% below its estimated fair value. The current Volatility is 51.73%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Volatility calculated?
Volatility is calculated from a company's financial statements. For Microba Life Sciences (ASX:MAP), the current Volatility is 51.73% as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Microba Life Sciences Business Description

Address 324 Queen Street, Level 10, Brisbane, QLD, AUS, 4000
Microba Life Sciences Ltd is a commercial-stage company with technology for measuring the human gut microbiome and engages in providing gut microbiome testing services globally to consumers, clinicians, and researchers. It is also involved in developing new pathology services, therapeutics, and diagnostics based on the human gut microbiome. The company's operating segments are: Testing Services and Supplements, which derive key revenue, and Research and Development. Geographically, the company derives maximum revenue from Australia and the rest from Europe, New Zealand, the United States, Asia, and other regions.